tiprankstipranks
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
US Market
RAPP
Rapport Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see RAPP full AI Analyst Report?

Rapport Therapeutics, Inc. (RAPP) Stock Forecast & Price Target

152 Followers
See the Price Targets and Ratings of:

RAPP Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Rapport
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RAPP Stock 12 Month Forecast

Average Price Target

$60.25
▲(14.76% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Rapport Therapeutics, Inc. in the last 3 months. The average price target is $60.25 with a high forecast of $75.00 and a low forecast of $50.00. The average price target represents a 14.76% change from the last price of $52.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","76":"$76","30.25":"$30.3","45.5":"$45.5","60.75":"$60.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,30.25,45.5,60.75,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.56,50.59384615384616,52.62769230769231,54.66153846153846,56.69538461538462,58.72923076923077,60.76307692307692,62.79692307692308,64.83076923076923,66.86461538461538,68.89846153846153,70.93230769230769,72.96615384615384,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.56,49.45923076923077,50.35846153846154,51.25769230769231,52.15692307692308,53.05615384615385,53.95538461538462,54.854615384615386,55.753846153846155,56.653076923076924,57.55230769230769,58.45153846153846,59.35076923076923,{"y":60.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.56,48.67076923076923,48.78153846153846,48.892307692307696,49.003076923076925,49.113846153846154,49.22461538461538,49.33538461538462,49.44615384615385,49.55692307692308,49.667692307692306,49.77846153846154,49.88923076923077,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.37,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.67,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.93,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.55,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.34,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.75,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.37,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.67,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.89,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.11,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.39,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.98,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.56,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$75.00Average Price Target$60.25Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on RAPP
Justin Walsh
JonesTrading
JonesTrading
$50
Buy
-4.76%
Downside
Reiterated
09/02/26
Analysts Conflicted on These NA Names: Fiserv (NASDAQ: FISV) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)
BTIG Analyst forecast on RAPP
Kambiz Yazdi
BTIG
BTIG
$65
Buy
23.81%
Upside
Reiterated
08/27/26
Analysts Offer Insights on NA Companies: Infleqtion (NYSE: INFQ) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)
William Blair Analyst forecast on RAPP
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/19/26
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (NASDAQ: RAPP) and SpaceX (NASDAQ: SPCX)
H.C. Wainwright Analyst forecast on RAPP
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$66
Buy
25.71%
Upside
Reiterated
08/17/26
H.C. Wainwright Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)
Raymond James Analyst forecast on RAPP
Tiago Fauth
Raymond James
Raymond James
$68→$75
Buy
42.86%
Upside
Reiterated
08/17/26
Rapport Therapeutics price target raised to $75 from $68 at Raymond JamesRapport Therapeutics price target raised to $75 from $68 at Raymond James
Stifel Nicolaus Analyst forecast on RAPP
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$56
Buy
6.67%
Upside
Reiterated
08/13/26
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus
Truist Financial Analyst forecast on RAPP
Danielle Brill
Truist Financial
Truist Financial
$56
Buy
6.67%
Upside
Reiterated
08/06/26
Truist Financial Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)
Goldman Sachs Analyst forecast on RAPP
Salveen Richter
Goldman Sachs
Goldman Sachs
$58→$62
Buy
18.10%
Upside
Reiterated
08/05/26
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (NASDAQ: RAPP) and Honeywell Aerospace (NASDAQ: HONA)
TD Cowen Analyst forecast on RAPP
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/17/26
Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (NASDAQ: RAPP) and Volvo Car AB Class B (Other OTC: VLVOF)
Leerink Partners Analyst forecast on RAPP
Marc Goodman
Leerink Partners
Leerink Partners
$52
Buy
-0.95%
Downside
Initiated
06/24/26
Rapport Therapeutics initiated with an Outperform at LeerinkRapport Therapeutics initiated with an Outperform at Leerink
Wells Fargo Analyst forecast on RAPP
Benjamin Burnett
Wells Fargo
Wells Fargo
$46
Buy
-12.38%
Downside
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (NASDAQ: RAPP), Danaher (NYSE: DHR) and Intuitive Surgical (NASDAQ: ISRG)
Citizens JMP Analyst forecast on RAPP
Jason Butler
Citizens JMP
Citizens JMP
$77→$80
Buy
52.38%
Upside
Reiterated
11/07/25
Rapport Therapeutics price target raised to $80 from $77 at Citizens JMPRapport Therapeutics price target raised to $80 from $77 at Citizens JMP
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on RAPP
Justin Walsh
JonesTrading
JonesTrading
$50
Buy
-4.76%
Downside
Reiterated
09/02/26
Analysts Conflicted on These NA Names: Fiserv (NASDAQ: FISV) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)
BTIG Analyst forecast on RAPP
Kambiz Yazdi
BTIG
BTIG
$65
Buy
23.81%
Upside
Reiterated
08/27/26
Analysts Offer Insights on NA Companies: Infleqtion (NYSE: INFQ) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)
William Blair Analyst forecast on RAPP
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/19/26
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (NASDAQ: RAPP) and SpaceX (NASDAQ: SPCX)
H.C. Wainwright Analyst forecast on RAPP
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$66
Buy
25.71%
Upside
Reiterated
08/17/26
H.C. Wainwright Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)
Raymond James Analyst forecast on RAPP
Tiago Fauth
Raymond James
Raymond James
$68→$75
Buy
42.86%
Upside
Reiterated
08/17/26
Rapport Therapeutics price target raised to $75 from $68 at Raymond JamesRapport Therapeutics price target raised to $75 from $68 at Raymond James
Stifel Nicolaus Analyst forecast on RAPP
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$56
Buy
6.67%
Upside
Reiterated
08/13/26
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus
Truist Financial Analyst forecast on RAPP
Danielle Brill
Truist Financial
Truist Financial
$56
Buy
6.67%
Upside
Reiterated
08/06/26
Truist Financial Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)
Goldman Sachs Analyst forecast on RAPP
Salveen Richter
Goldman Sachs
Goldman Sachs
$58→$62
Buy
18.10%
Upside
Reiterated
08/05/26
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (NASDAQ: RAPP) and Honeywell Aerospace (NASDAQ: HONA)
TD Cowen Analyst forecast on RAPP
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/17/26
Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (NASDAQ: RAPP) and Volvo Car AB Class B (Other OTC: VLVOF)
Leerink Partners Analyst forecast on RAPP
Marc Goodman
Leerink Partners
Leerink Partners
$52
Buy
-0.95%
Downside
Initiated
06/24/26
Rapport Therapeutics initiated with an Outperform at LeerinkRapport Therapeutics initiated with an Outperform at Leerink
Wells Fargo Analyst forecast on RAPP
Benjamin Burnett
Wells Fargo
Wells Fargo
$46
Buy
-12.38%
Downside
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (NASDAQ: RAPP), Danaher (NYSE: DHR) and Intuitive Surgical (NASDAQ: ISRG)
Citizens JMP Analyst forecast on RAPP
Jason Butler
Citizens JMP
Citizens JMP
$77→$80
Buy
52.38%
Upside
Reiterated
11/07/25
Rapport Therapeutics price target raised to $80 from $77 at Citizens JMPRapport Therapeutics price target raised to $80 from $77 at Citizens JMP
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rapport Therapeutics, Inc.

3 Months
Joseph ThomeTD Cowen
Success Rate
11/15 ratings generated profit
73%
Average Return
+10.16%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +10.16% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
6/7 ratings generated profit
86%
Average Return
+73.27%
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +73.27% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
15/15 ratings generated profit
100%
Average Return
+133.05%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +133.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RAPP Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
5
5
3
2
Buy
10
8
7
15
15
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
13
12
18
17
In the current month, RAPP has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RAPP average Analyst price target in the past 3 months is 60.25.
Each month's total comprises the sum of three months' worth of ratings.

RAPP Financial Forecast

RAPP Earnings Forecast

Next quarter’s earnings estimate for RAPP is -$1.20 with a range of -$1.36 to -$1.02. The previous quarter’s EPS was -$1.19. RAPP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year RAPP has Performed in-line its overall industry.
Next quarter’s earnings estimate for RAPP is -$1.20 with a range of -$1.36 to -$1.02. The previous quarter’s EPS was -$1.19. RAPP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year RAPP has Performed in-line its overall industry.

RAPP Sales Forecast

Next quarter’s sales forecast for RAPP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. RAPP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year RAPP has Performed in-line its overall industry.
Next quarter’s sales forecast for RAPP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. RAPP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year RAPP has Performed in-line its overall industry.

RAPP Stock Forecast FAQ

What is RAPP’s average 12-month price target, according to analysts?
Based on analyst ratings, Rapport Therapeutics, Inc.’s 12-month average price target is 60.25.
    What is RAPP’s upside potential, based on the analysts’ average price target?
    Rapport Therapeutics, Inc. has 14.76% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RAPP a Buy, Sell or Hold?
          Rapport Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Rapport Therapeutics, Inc.’s price target?
            The average price target for Rapport Therapeutics, Inc. is 60.25. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $75.00 ,the lowest forecast is $50.00. The average price target represents 14.76% Increase from the current price of $52.5.
              What do analysts say about Rapport Therapeutics, Inc.?
              Rapport Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of RAPP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.